Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2018 - 2026)

Mirum Pharmaceuticals' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $386.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 39.11% year-over-year to $386.3 million; the TTM figure through Mar 2026 stood at $386.3 million (up 39.11% YoY), while the FY2025 annual figure was $383.3 million, up 36.54% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $386.3 million, up from $383.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $434.9 million in Q3 2022, with the low at $94.0 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $286.3 million (2023), against an average of $280.5 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments jumped 129.3% in 2024, then plunged 66.95% in 2025.
• Mirum Pharmaceuticals' Cash & Current Investments stood at $251.7 million in 2022, then gained by 13.75% to $286.3 million in 2023, then decreased by 1.95% to $280.7 million in 2024, then soared by 36.54% to $383.3 million in 2025, then advanced by 0.76% to $386.3 million in 2026.
• Business Quant data shows MIRM's Cash & Current Investments at $386.3 million in Q1 2026, $383.3 million in Q4 2025, and $94.0 million in Q3 2025.